Dr. Alcorn joined DiaMedica in August 2018.
Before joining DiaMedica, Dr. Alcorn served as Chief Scientific Officer of Total Renal Research, Inc., doing business as DaVita Clinical Research (DCR), a clinical research facility, from November 1997 to July 2018. While at DCR, Dr. Alcorn was responsible for clinical research operations, including management of the early clinical research unit. Dr. Alcorn also designed and created the U.S. Renal Network, the first network of Phase I renal research sites in the U.S. Dr. Alcorn developed DCR's site management organization for clinical trials. Dr. Alcorn also served as an Executive Director, a Pharmacist, and an Investigator at DCR From March 1996 to November 1997, Dr. Alcorn served as Executive Director of Clinical Programs for GalaGen, Inc., a Pharmaceutical company. From March 1992 to March 1996, Dr. Alcorn served as Vice President, Marketing/Sales and Clinical Programs of In Home Health, Inc., a national home health provider. Dr. Alcorn served on the board of directors of Medtox Scientific Inc.
Dr. Alcorn is also a Clinical Assistant Professor at Creighton University School of Pharmacy, Virginia Commonwealth University School of Pharmacy, University of Minnesota, College of Pharmacy, and University of Nebraska Medical Center, College of Pharmacy. Dr. Alcorn is also on the adjunct clinical faculty at the University of Colorado. Dr. Alcorn graduated from Creighton University with his B.S. in Pharmacy and received his Pharm.D. from the University of Nebraska Medical Center.
What is Harry W. Alcorn, Jr.'s net worth?
The estimated net worth of Harry W. Alcorn, Jr. is at least $174,763.82 as of September 15th, 2021. Dr. Alcorn, Jr. owns 43,582 shares of DiaMedica Therapeutics stock worth more than $174,764 as of November 17th. This net worth approximation does not reflect any other investments that Dr. Alcorn, Jr. may own. Learn More about Harry W. Alcorn, Jr.'s net worth.
How do I contact Harry W. Alcorn, Jr.?
Has Harry W. Alcorn, Jr. been buying or selling shares of DiaMedica Therapeutics?
Harry W. Alcorn, Jr. has not been actively trading shares of DiaMedica Therapeutics during the last quarter. Most recently, on Wednesday, September 15th, Harry W. Alcorn, Jr. bought 15,000 shares of DiaMedica Therapeutics stock. The stock was acquired at an average cost of $3.80 per share, with a total value of $57,000.00. Following the completion of the transaction, the senior vice president now directly owns 43,582 shares of the company's stock, valued at $165,611.60. Learn More on Harry W. Alcorn, Jr.'s trading history.
Who are DiaMedica Therapeutics' active insiders?
Are insiders buying or selling shares of DiaMedica Therapeutics?
During the last twelve months, DiaMedica Therapeutics insiders bought shares 1 times. They purchased a total of 1,200,000 shares worth more than $3,000,000.00. The most recent insider tranaction occured on June, 28th when Major Shareholder Koch Thomas Von bought 1,200,000 shares worth more than $3,000,000.00. Insiders at DiaMedica Therapeutics own 7.2% of the company.
Learn More about insider trades at DiaMedica Therapeutics. Information on this page was last updated on 6/28/2024.
